Clarity fuel
I was happy to see this full-page ad while reading the Wall Street Journal this week, because finally, a biopharma company did a great job communicating clearly in human-ready language: Gilead …
Continue Reading about An A+ for the new Gilead Sciences campaign: Creating Possible →
***** TODAY’S NEWS Hugely encouraging results for Novartis' new experimental (oral) MS treatment - Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients …
TODAY’S NEWS Big news on the leukemia front: Novartis' Tasigna gets priority FDA review for newly-diagnosed patients; and Roche/Genentech's Rituxan approved for CLL. A quarter of new prescriptions …
Glaxo: more big cuts, and the U.S. HQ needle pointing south - GlaxoSmithKline (GSK) announced that it will reduce its sales personnel by 12% to 7,500 down from 8,500. The company will slash 1,800 jobs …
Sanofi-Aventis suspends sale of Acomplia in Europe. Acomplia, an obesity drug that once looked like it would be a blockbuster for Sanofi-Aventis, is being pulled off the market in Europe. The EMEA, …
